Back to Search Start Over

Smoking and response to rituximab in rheumatoid arthritis:results from an international European collaboration

Authors :
Chatzidionysiou, K
Lukina, G
Gabay, C
Hetland, M L
Hauge, E M
Pavelka, K
Nordström, D
Canhão, H
Tomsic, M
Rotar, Z
Lie, E
Kvien, T K
van Vollenhoven, R F
Saevarsdottir, S
Chatzidionysiou, K
Lukina, G
Gabay, C
Hetland, M L
Hauge, E M
Pavelka, K
Nordström, D
Canhão, H
Tomsic, M
Rotar, Z
Lie, E
Kvien, T K
van Vollenhoven, R F
Saevarsdottir, S
Source :
Chatzidionysiou , K , Lukina , G , Gabay , C , Hetland , M L , Hauge , E M , Pavelka , K , Nordström , D , Canhão , H , Tomsic , M , Rotar , Z , Lie , E , Kvien , T K , van Vollenhoven , R F & Saevarsdottir , S 2019 , ' Smoking and response to rituximab in rheumatoid arthritis : results from an international European collaboration ' , Scandinavian Journal of Rheumatology , vol. 48 , no. 1 , pp. 17-23 .
Publication Year :
2019

Abstract

OBJECTIVES: To investigate whether smoking habits predict response to rituximab (RTX) in rheumatoid arthritis (RA).METHOD: We included patients from the CERERRA international cohort receiving the first treatment cycle with available smoking status (n = 2481, smokers n = 528, non-current smokers n = 1953) and at least one follow-up visit. Outcome measures were change in Disease Activity Score based on 28-joint count (ΔDAS28) and European League Against Rheumatism (EULAR) good response at 6 months, with non-current smokers as the referent group.RESULTS: Compared with non-smokers at baseline, smokers were more often rheumatoid factor (RF)/anti-citrullinated protein antibody (ACPA) positive and males, had shorter disease duration, lower DAS28 and Health Assessment Questionnaire (HAQ) score, a higher number of prior biological disease-modifying anti-rheumatic drugs, and were more likely to receive concomitant conventional synthetic disease-modifying anti-rheumatic drug (csDMARDs). Disease activity had decreased less in smokers at 6 months (ΔDAS28 = 1.5 vs 1.7, p = 0.006), although the difference was no longer significant after correction for baseline DAS28 (p = 0.41). EULAR good response rates did not differ between smokers and non-smokers overall or stratified by RF/ACPA status, although smokers had lower good response rates among seronegative patients (ACPA-negative: 6% vs 14%, RF-negative: 11% vs 18%). Smoking did not predict good response [odds ratio (OR) = 1.04, 95% confidence interval (CI) = 0.76-1.41], while ACPA, DAS28, HAQ, and concomitant csDMARDs were significant predictors for good response. However, when stratified by country, smokers were less likely to achieve good response in Sweden (unadjusted OR = 0.24, 95% CI = 0.07-0.89), and a trend was seen in the Czech Republic (OR = 0.45, 95% CI = 0.16-1.02).CONCLUSION: In this large, observational, multinational RA cohort, smokers starting RTX differed from non-smokers by having shorter di

Details

Database :
OAIster
Journal :
Chatzidionysiou , K , Lukina , G , Gabay , C , Hetland , M L , Hauge , E M , Pavelka , K , Nordström , D , Canhão , H , Tomsic , M , Rotar , Z , Lie , E , Kvien , T K , van Vollenhoven , R F & Saevarsdottir , S 2019 , ' Smoking and response to rituximab in rheumatoid arthritis : results from an international European collaboration ' , Scandinavian Journal of Rheumatology , vol. 48 , no. 1 , pp. 17-23 .
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1140010128
Document Type :
Electronic Resource